Results 181 to 190 of about 83,454 (234)
Some of the next articles are maybe not open access.
Transdermal delivery of antisense compounds
Advanced Drug Delivery Reviews, 2000Antisense technology holds tremendous promise for therapeutic applications and the study of gene function. A broadly applicable route of administration that would provide for non-invasive, simple, and convenient delivery is highly desirable. Application of oligonucleotides to the skin may represent a solution to the delivery question for both local ...
R M, Brand, P L, Iversen
openaire +2 more sources
Transdermal Delivery of Antisense Oligonucleotides
2004In recent years, antisense oligodeoxynucleotides (ODNs) have emerged as promising biopharmaceutical therapeutics. These agents specifically target genes or gene transcripts involved in pathogenesis. Several clinical trials have demonstrated the therapeutic value and low toxicity of ODNs (1–5).
Rhonda M, Brand, Patrick L, Iversen
openaire +3 more sources
Antisense oligonucleotides: strategies for delivery
Pharmaceutical Science & Technology Today, 1998Abstract The development of antisense oligonucleotides as therapeutic agents has progressed significantly over the past 10–15 years. In order for antisense oligodeoxynucleotides to become effective therapeutic agents, improvement in the delivery and distribution of these compounds must occur.
Keith J Miller, Sudip K Das
openaire +1 more source
Oral Delivery of Antisense Oligonucleotides in Man
Journal of Pharmaceutical Sciences, 2008Treatment of systemic disease with phosphorothioate antisense oligonucleotides (PS ASOs) has been accomplished using local or parenteral routes of administration to date. This report describes, for the first time, the effective oral delivery of a second generation oligonucleotide where significant milligram amounts of intact drug are absorbed in human ...
Lloyd G, Tillman +2 more
openaire +2 more sources
Comparison of antisense oligonucleotide drug delivery systems
Journal of Controlled Release, 2004Antisense oligonucleotides (AS-ONs) are specific drugs to inhibit gene expression at the transcriptional level. They possess a poor bioavailability and can be degraded by nucleases very rapidly. Therefore, a strong need for the development of oligonucleotide drug delivery systems exists. In the present study, two commercially available liposomes (DOTAP,
Jörg, Weyermann +2 more
openaire +2 more sources
Delivery of antisense oligonucleotides to PC12 cells
Neuroscience Research, 2002Optimal experimental conditions for the delivery of phosphodiester or phosphorothioate antisense oligonucleotides (P-ASO/S-ASO) to PC12 cells were determined. Fluorescently labeled P-ASO or S-ASO were transfected to PC12 cells and the uptake of antisense, free or entrapped in liposomes, was monitored by confocal and fluorescent microscopy.
Rosalinda, Acosta +3 more
openaire +2 more sources
Targeted Lipid Nanoparticles for Antisense Oligonucleotide Delivery
Current Pharmaceutical Biotechnology, 2014Antisense oligonucleotides (AS-ODNs) are short, single-stranded DNA molecules designed to bind specifically to a target messenger RNA (mRNA) and down-regulate gene expression. Despite being a promising class of therapeutics for a variety of diseases, they face major hurdles limiting their clinical application, including low intracellular delivery and ...
Raquel, Petrilli +4 more
openaire +2 more sources
Delivery of antisense oligonucleotides to neuroblastoma cells
NeuroReport, 2000pH-Sensitive liposomes composed of dioleoylphosphatidylethanolamine and cholesterol hemisuccinate (3:2 mol/mol) were applied in delivery of antisense oligodeoxynucleotides (asODN) into NG 108-15 neuroblastoma and glioma cells. Fluorescently labelled asODN were entrapped in liposomes by a modified freeze-thawing method (20% encapsulation efficiency ...
N, Skalko-Basnet, M, Tohda, H, Watanabe
openaire +2 more sources
Novel non-endocytic delivery of antisense oligonucleotides
Advanced Drug Delivery Reviews, 2000Antisense oligonucleotides (ONs) have several properties that make them attractive as therapeutic agents. Hybridization of antisense ONs to their complementary nucleic acid sequences by Watson-Crick base pairing is a highly selective and efficient process.
S, Dokka, Y, Rojanasakul
openaire +2 more sources
Blended Block Polycation Micelles Enhance Antisense Oligonucleotide Delivery
Bioconjugate Chemistry, 2023Nucleic acid-based medicines and vaccines are becoming an important part of our therapeutic toolbox. One key genetic medicine is antisense oligonucleotides (ASOs), which are short single-stranded nucleic acids that downregulate protein production by binding to mRNA. However, ASOs cannot enter the cell without a delivery vehicle.
Mckenna G. Hanson +4 more
openaire +2 more sources